Company Description
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs.
It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.
The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus.
It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally.
Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine.
The company was founded in 1998 and is based in Saint-Herblain, France.
| Country | France |
| Founded | 2012 |
| IPO Date | May 6, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 676 |
| CEO | Thomas Lingelbach |
Contact Details
Address: 6 rue Alain Bombard Saint-Herblain, 44800 France | |
| Phone | 33 2 28 07 37 10 |
| Website | valneva.com |
Stock Details
| Ticker Symbol | VALN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| IPO Price | $26.41 |
| CIK Code | 0001836564 |
| CUSIP Number | 92025Y103 |
| ISIN Number | US92025Y1038 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Thomas Lingelbach | President, Chief Executive Officer and Director |
| Peter Buhler | Chief Financial Officer |
| Franck Grimaud MBA | Chief Business Officer |
| Dr. Juan-Carlos Jaramillo M.D. | Chief Medical Officer |
| Dipal Patel | Chief Commercial Officer |
| Vincent Dequenne | Chief Operating Officer |
| Dr. Hanneke Schuitemaker Ph.D. | Chief Scientific Officer |
| Joshua Drumm Ph.D. | Vice President of Investor Relations |
| Laetitia Bachelot-Fontaine | Vice President of Global Communications and European Investor Relations |
| Petra Pesendorfer | Chief People Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 13, 2024 | 6-K | Report of foreign issuer |
| Nov 7, 2024 | 6-K | Report of foreign issuer |
| Oct 21, 2024 | 6-K | Report of foreign issuer |
| Oct 16, 2024 | 6-K | Report of foreign issuer |
| Oct 10, 2024 | 6-K | Report of foreign issuer |
| Oct 3, 2024 | 6-K | Report of foreign issuer |
| Sep 20, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Sep 18, 2024 | 6-K | Report of foreign issuer |
| Sep 13, 2024 | 6-K | Report of foreign issuer |
| Sep 3, 2024 | 6-K | Report of foreign issuer |